Thomas Enzler
YOU?
Author Swipe
View article: Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma?
Pancreatic cancer precursor lesions – Can immunotherapy prevent progression into pancreatic ductal adenocarcinoma? Open
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate of only 12.5 %. Early detection of PDAC or addressing risk factors for PDAC development are ways to improve outcomes. PDAC can arise from …
View article: 6888 Sequencing Endocrinologic And Oncologic Treatments For A Patient With A Metastatic High-Grade Neuroendocrine Tumor And The Ectopic Acth Syndrome
6888 Sequencing Endocrinologic And Oncologic Treatments For A Patient With A Metastatic High-Grade Neuroendocrine Tumor And The Ectopic Acth Syndrome Open
Disclosure: C. Villatoro Santos: None. C. Alvarado Nieves: None. T. Enzler: None. R.J. Auchus: None. Ectopic ACTH syndrome (EAS) from neuroendocrine tumors (NETs) is a rare cause of hypercortisolism. We present a patient with a metastatic …
View article: Supplementary Table S4 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S4 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Genomics data
View article: Supplementary Table S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Agilent and Resipher Assays in the TKF-1, RCB1292 and RCB1293 BTC Cell Lines in Figure 1B and 1C
View article: Supplementary Table S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Prior and Posterior Estimates for Probability of Dose-Limiting Toxicity
View article: Supplementary Figure S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Figure S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Mutational Landscape of Biliary Tract Cancer Cell Lines
View article: Data from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Data from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Purpose: Devimistat (CPI-613®) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated effect of devimistat in vitro and in a phase 1b clinical trial in patients with advanced biliary tract cancer (BTC). Patients and Meth…
View article: Supplementary Table S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Representativeness of Study Participants
View article: Supplementary Table S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Prior and Posterior Estimates for Probability of Dose-Limiting Toxicity
View article: Supplementary Table S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Agilent and Resipher Assays in the TKF-1, RCB1292 and RCB1293 BTC Cell Lines in Figure 1B and 1C
View article: Supplementary Figure S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Figure S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
IC50 values for devimistat in biliary cancer cell lines
View article: Supplementary Figure S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Figure S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Study Schema
View article: Supplementary Figure S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Figure S3 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
IC50 values for devimistat in biliary cancer cell lines
View article: Supplementary Table S4 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S4 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Genomics data
View article: Supplementary Figure S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Figure S1 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Study Schema
View article: Supplementary Figure S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Figure S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Mutational Landscape of Biliary Tract Cancer Cell Lines
View article: Supplementary Table S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04)
Supplementary Table S2 from Devimistat in combination with gemcitabine and cisplatin in biliary tract cancer: Pre-clinical evaluation and phase 1b multicenter clinical trial (BilT-04) Open
Representativeness of Study Participants
View article: A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions
A Comparison of Spatial and Phenotypic Immune Profiles of Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions Open
Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a 5-year survival rate of 12.5%. PDAC predominantly arises from non-cystic pancreatic intraepithelial neoplasia (PanIN) and cystic intraductal papillary mucinous neoplas…
View article: Supplementary Table S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Table S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Representativeness of Study Participants
View article: Supplementary Table S3 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Table S3 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Prior and Posterior Estimates for Probability of Dose-Limiting Toxicity
View article: Supplementary Table S4 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Table S4 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Genomics data
View article: Supplementary Figure S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Figure S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Mutational Landscape of Biliary Tract Cancer Cell Lines
View article: Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Study Schema
View article: Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Study Schema
View article: Supplementary Table S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Table S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Agilent and Resipher Assays in the TKF-1, RCB1292 and RCB1293 BTC Cell Lines in Figure 1B and 1C
View article: Data from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Data from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Purpose:Devimistat (CPI-613) is a novel inhibitor of tumoral mitochondrial metabolism. We investigated the effect of devimistat in vitro and in a phase Ib clinical trial in patients with advanced biliary tract cancer (BTC).Patients and Met…
View article: Supplementary Table S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Table S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Agilent and Resipher Assays in the TKF-1, RCB1292 and RCB1293 BTC Cell Lines in Figure 1B and 1C
View article: Supplementary Figure S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
Supplementary Figure S2 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04) Open
Mutational Landscape of Biliary Tract Cancer Cell Lines